On January 27, 2025 LinkedIn founder Reid Hoffman and Siddhartha Mukherjee, cancer researcher and author of the book "The Emperor of All Maladies," reported they have co-founded an AI-powered drug discovery startup, Manas AI (Press release, Manas AI, JAN 27, 2025, View Source [SID1234656925]). The company, which will initially focus on breast cancer, prostate cancer, and lymphoma, has raised $24.6 million in seed funding from Hoffman, General Catalyst, and Greylock.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Manas AI’s capital haul pales compared with some other startups trying to use AI models to develop novel drugs. Last year, Xaira, which claimed that it was ready to start developing drugs, launched with a massive $1 billion in initial funding. Treeline Biosciences is another company that uses AI for drug discovery and raised $422 million last year, Endpts reported.

Manas AI claims it will design molecules with AI, then test them in a wet lab, Hoffman reportedly said during the presentation of his new book "Superagency." The outfit also says it will use Microsoft’s cloud computing platform, Azure, and Microsoft’s "deep domain knowledge in AI" to develop novel medicines.

Hoffman has close ties to Microsoft, which famously acquired his earlier company, LinkedIn, in a blockbuster deal in 2016.